Bevacizumab biosimilar (Reliance Life Sciences)

贝伐珠单抗生物类似药 (Reliance Life Sciences)

Report date: 2022/03/16 17:50:56

Base Information

Drug NameBevacizumab biosimilar (Reliance Life Sciences)

Drug Alias Name贝伐赛珠单抗生物仿制药 (Reliance Life Sciences)贝伐单抗生物仿制药 (Reliance Life Sciences)贝伐珠单抗生物仿制药 (Reliance Life Sciences)贝伐人源化单抗生物仿制药(Reliance Life Sciences)BevaciRel +[6]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8]

Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8]

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2016/06/13

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesReliance Life Sciences

China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences

Inactive CompaniesN/A

Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8]

Inactive IndicationsN/A

Other Information

ATC CodeL01XC07